Prof. Dr. Andreas Mackensen



close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Case Report: IBD-like colitis following CAR T cell therapy for diffuse large B cell lymphoma (2023) Zundler S, Vitali F, Kharboutli S, Völkl S, Polifka I, Mackensen A, Atreya R, et al. Journal article The metabolic profile of reconstituting T-cells, NK-cells, and monocytes following autologous stem cell transplantation and its impact on outcome (2022) Richter S, Böttcher M, Mackensen A, Ullrich E, Jacobs B, Mougiakakos D, Völkl S Journal article Blocking the CD47-Sirpa Axis Enhances Tafasitamab-Mediated Phagocytosis (2022) Biedermann A, Mangelberger-Eberl D, Mougiakakos D, Büttner-Herold M, Flamann C, Kellner C, Altmeyer S, et al. Conference contribution Sars-Cov-2 Vaccine-Induced Cellular and Humoral Immunity in Patients after CD19.CAR-T Cell Therapy (2022) Reimann H, Kremer A, Blumenberg V, Schmidt K, Aigner M, Kremer A, Tenbusch M, et al. Conference contribution Detection of Signature Double-Negative T Cells Is a Reliable Marker for ALPS Associated with FAS Mutation (2022) Eisenhauer N, Miano M, Naumann-Bartsch N, Leyh J, Terranova P, Hinze C, Aigner M, et al. Conference contribution Early Real Time Quantification of CD19. CAR T Cells By Flow Cytometry As a Predictive Biomarker for Response in Patients with R/R LBCL (2022) Blumenberg V, Busch G, Baumann S, Jitschin R, Winkelmann M, Hellwig K, Rejeski K, et al. Conference contribution Inferior Outcomes of EU Vs. US Patients with Relapsed/Refractory Large B-Cell Lymphoma after CD19 CAR T-Cell Therapy Are Associated with Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization and CAR-T Product Selection (2022) Buecklein VL, Perez-Perez A, Rejeski K, Iacoboni G, Jurinovic V, Holtick U, Penack O, et al. Conference contribution Biphasic Neutrophil Recovery after CD19 CART in R/R LBCL Is Associated with Superior PFS/OS, Robust CAR T-Cell Expansion in Relation to Baseline Tumor Volume, and a Decrease of Systemic Inflammation over Time (2022) Rejeski K, Perez AP, Iacoboni G, Buecklein VL, Blumenberg V, Völkl S, Penack O, et al. Conference contribution Expansion of Plasmablasts at Day 90 after Allogeneic Stem Cell Transplantation Predict Chronic Gvhd (2022) Habenicht KM, Bootz A, Schäfer S, Vasova I, Fante M, Schneider A, Rehli M, et al. Conference contribution CD19-Targeted CAR-T Cells in Refractory Systemic Lupus Erythematosus: Safety, Efficacy, and Mechanistic Insights from the First Five Patients (2022) Müller F, Völkl S, Mougiakakos D, Böltz S, Aigner M, Gary R, Kretschmann S, et al. Conference contribution